MDD Benchmark is a data driven performance improvement continuing medical education (PI CME) initiative that is designed to address and improve the quality of care and health outcomes for patients with Major Depressive Disorder (MDD). The programs goals are to equip psychiatrists and associated mental health professionals to improve their knowledge and skills in using data metrics, published guidelines, and prescriptions in the management and care of patients with adult MDD. Participants will be given access to their quality and performance data on a quarterly basis to provide a reflection of their performance against nationally accepted standards for the quality of care for people with MDD.
This PI CME activity has been approved for a maximum of 20 AMA PRA Category 1 CreditsTM.
Jointly sponsored by the Duke University School of Medicine and Direct One Communications.
Statement of Need
MDD affects 6.7% (19 million) of adults in the United States; 30.4% of these cases–2.0% of adult Americans–are considered severe. Depression is the leading cause of disability worldwide, in terms of years lost due to disability, and ranks first in middle- and high-income countries when measured by years of potential life lost due to premature mortality and years of productive life lost due to disability. Different studies have consistently demonstrated that people with depression experience impaired physical and role functioning, more days in bed due to illness, more work days lost, increased impairment at work, and higher utilization of health services. At its worst, depression can lead to suicide. One percent of all deaths in the US are due to suicide, and nearly two thirds of all suicides have been attributed to depression. A systematic review of various suicide prevention strategies concluded that physician education in recognizing and treating depression, as well as restricting access to firearms and other lethal means, can reduce suicide rates by 22% to 73%.
After participating in this educational curriculum, participants should be able to:
- Improve psychiatrists’ knowledge and competency for the assessment of depressive symptoms and the importance of routinely utilizing validated instruments to monitor disease severity and health status changes related to MDD;
- Increase the clinical knowledge and skills regarding the use of validated instruments to accurately assess and monitor functional status for their patients with MDD;
- Improve competencies amongst psychiatrists about clinical guidelines for MDD, stressing the importance of effective clinical management in increasing patients’ medication compliance, monitoring treatment effectiveness, and identifying and managing side effects and how proper management may lead;
- Decrease recurrence of depression;
- Improve the knowledge amongst psychiatrists for appropriate medication management including new class of drugs, augmentation, and total daily dosing.
This activity is intended to provide educational information related to MDD patient management and is intended for psychiatrists and the supporting coordinated mental health care team including, the MindLinc Behavioral Health Network and all US-based psychiatrists and the supporting coordinated healthcare team who treat people with MDD.
This CME activity is supported by educational grants from Bristol-Myers Squibb and Pfizer, Inc.